choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Ziagen

Ziagen Newsletter
  • Some Children Treated Very Early Have Sustained HIV Remission 07 Mar 2024 20:44 GMT

    … of children who start HIV treatment within the first … Hopkins University School of Medicine, reported. Deborah Persaud … end, researchers launched a trial called IMPAACT P1115 (NCT02140255 … AZT (Retrovir) or abacavir (Ziagen), lamivudine (Epivir) and nevirapine …

  • Some children who start antiretrovirals very early may control HIV after stopping treatment 07 Mar 2024 11:05 GMT

    … daily medication. Taking a planned break from HIV treatment, sometimes known as a ‘drugs … learn more, researchers launched a trial called IMPAACT P1115 (NCT02140255), funded … HIV during gestation. They initially received AZT (Retrovir) or abacavir (Ziagen

  • Could Very Early Treatment Cure Babies Born With HIV? 13 Dec 2023 18:56 GMT

    … Hopkins University School of Medicine reported the case … very early treatment. While ART can suppress HIV replication indefinitely … three-drug regimen of AZT (Retrovir) or abacavir (Ziagen), lamivudine … noted. As the trial continues, the researchers plan …

  • Netherlands Man in Remission 23 Years After Stopping HIV Treatment 22 Nov 2023 22:18 GMT

    … stopping HIV treatment, according to a case report described in the journal AIDS … five-drug regimen consisting of stavudine (d4T), lamivudine (3TC), abacavir (Ziagen), the … ’ seven months after stopping treatment. However, plasma HIV RNA was detectable at …

  • HIV Type-1 Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Developing Therapies - ViiV Healthcare, GlaxoSmithKline, PPD, Merck, Gilead, Janssen, AbbVie, Sanofi 02 Nov 2023 17:00 GMT

    … Ireland UC, Vir Biotechnology, Inc., National Institute … (ARV) medications for HIV treatment are categorized into … FDA-approved drugs for HIV type-1 @ Drugs for HIV Type-1 Treatment  Key HIVHIV type-1 clinical trials, visit @ HIV Type-1 Treatment Drugs  HIV

  • Antiretroviral drugs: what Abacavir oral solution is and what it does 11 Jan 2023 11:10 GMT

    … COMMON BRAND NAME(S): Ziagen, Ziagen Solution What should I tell … of all the medicines, herbs, non-prescription drugs, or dietary … medicine, stop the medicine and call your doctor right away. This medicine … : Kaposi’s Sarcoma World AIDS Day: New Procedure To …

  • A Call to Action on HIV 26 Nov 2022 22:10 GMT

    … and suitability of services, for HIV treatment, testing and prevention, so that … has been paid to HIV/AIDS. But the latest statistics … ART). A combination of drugs such as Ziagen, Emtriva, Epivir and Viread … But AIDS could be a thing of the past if medical

  • Explaining HIV and AIDS 25 Jul 2022 16:22 GMT

    … stage of HIV. Doctors identify AIDS as having … at HIV treatments and medications for prevention. Emergency HIV pills: PEP … medicine Many people with HIV try complementary, alternative, or herbal remedies … The Food and Drug Administration (FDA) has also …

  • More Cardiac Abnormalities Seen in People Living With HIV 26 Apr 2022 17:48 GMT

    … in HIV (REPRIEVE) trial comes in. The study is testing whether a statin medication … NRTI abacavir (Ziagen, also in the Epzicom and Triumeq combination pills), which … no other significant associations between HIV treatment regimens and baseline ECG results …

  • Weight Gain Persists as HIV-Treatment Issue 07 Aug 2020 18:38 GMT

    … useful and relatively new drug, tenofovir alafenamide fumarate ( … of the International AIDS conference. The women … medicine and site leader of the HIV Prevention and Treatment Clinical Trials … The DRIVE-SHIFT trial enrolled 670 HIV patients with successfully …

Satisfied with the content?

Continue to create your account.